Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits

British Journal of Pharmacology

Volumn 126, Issue 4, 1999, Pages 961-968

  Shiomi, Masashi ^a   Ito, Takashi ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Cerivastatin; Coronary stenosis; HMG CoA reductase inhibitor; Macrophage; Plasma cholesterol; Smooth muscle cell; WHHL rabbit

Indexed keywords

CERIVASTATIN; CHOLESTEROL; COLLAGEN FIBER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032962809     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702382     Document Type: Article

References (30)

1. ANGERBAUER, R., BISCHOFF, H., STEINKE, W. & RITTER, W. (1994). BAY w 6228: Hypolipidemic HMG-CoA reductase inhibitor. Drugs of the Future, 19, 537-541.
2. BANDOH, T., MITANI, H., NIIHASHI, M-, KUSUMI, Y., ISHIKAWA, J., KIMURA, M., TOTSUKA, T., SAKURAI, I. & HAYASHI, S. (1996). Inhibitory effect of fluvastatin at doses insufficient to low serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur. J. PharmacoL, 315, 37-42.
3. BELLOSTA, S., BERNINI, F., FERRI, N., QUARATO, P., CANAVESI, M., ARNABOLDI, L., FUMAGALLI, R., PAOLETTI, R., CORSINI, A. (1998). Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis, 137 Suppl., S101-S109.
4. BISCHOFF, H., ANGERBAUER, R., BENDER, J., BISCHOFF, E., FAGGIOTTO, A., PETZINNA, D., PFITZNER, J., PORTER, M.C., SCHMIDT, D. & THOMAS, G. (1997). Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis, 135, 119-130.
5. CORSINI, A., ARNABOLDI, L., RAITERI, M., QUARATO, P., FAGGIOTTO, A., PAOLETTI, R. & FUMAGALLI, R. (1996). Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY w 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. PharmacoL Res., 33, 55-61.
6. DAVIES, M.J. (1995). Acute coronary thrombosis, the role of plaque disruption and its inhibition and prevention. Eur. Heart J., 16 (Suppl L), 3-7.
7. DAVIES, M.J., RICHARDSON, P.D., WOOLF, N., KATZ, D.R. & MANN, J. (1993). Risk of thrombosis in human atherosclerotic plaques; role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J., 69, 377-381.
8. DOWNS, J.R., CLEARFIELD, M., WEIS, S., WHITNEY, E., SHAPIRO, D.R., BEERE, P.A., LANGENDORFER, A., STEIN, E.A., KRUYER, W. & GOTTO, A.M. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA, 279, 1615-1622.
9. GALIS, Z.S., SUKHOVA, O.K., KRANZHOFER, R., CLARK, S. & LIBBY, P. (1995). Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Nail. Acad. Sei. USA. 92, 402-406.
10. IGARASHI, M..TAKEDA, Y., MORI, S., ISHIBASHI, N., KOMATSU, E., TAKAHASHI, K., FUSE, T., YAMAMURA, M., SUGIYAMA, Y. & SAITO, Y. (1997a). BAYw6228 suppresses accumulation of macrophages in balloon-induced intimai thickening of rabbit carotid artery. Atherosclerosis, 128, 251-254.
11. IGARASHI, M., TAKEDA, Y., MORI, S., ISHIBASHI, N., KOMATSU, E., TAKAHASHI, K., FUSE, T., YAMAMURA, M., KUBO, K., SUGIYAMA, Y. & SAITO, Y. (1997b). Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br. J. Pharmacol., 120, 1172-1178.
12. KROL, G.J., BECK, G.W., RITTER, W. & LETTIERI, J.T. (1993). LC separation and induced fluorometric detection of rivastatin in blood plasma. J. Pharmacol. Biomed. Anal., 11, 1269-1275.
13. LIBBY, P. (1995). Molecular Bases of acute coronary syndrome. Circulation, 91, 2844-2850.
14. NEGRE-AMINOU, P., VAN VLIET, A.K., VAN ERCK, M., VAN THIEL, G.C., VAN LEEUWEN, R.E. & COHEN, L.H. (1997). Inhibition of proliferation of human smooth muscle cells by various HMGCoA reductase inhibitors; comparison with other human cell types. Biochim. Biophys. Acta., 1345, 259-268.
15. ROSENSON, S.R. & TANGNEY, C.C. (1988). Antiatherosclerotic properties of statins: Implications for cardiovascular event reduction. JAMA, 279, 1643-1650.
16. SCANDINAVIA SIMVASTATIN SURVIVAL STUDY GROUP. (1994). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavia Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
17. SHEPHERED, J., COBBE, S.M., FORD, I., ISLES, CO., LORIMER, A.R., MACFARLANE, P.W., MCKILLOP, J.H. & PACKARD, c.j. (1995)' Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333, 1301 -1307.
18. SHIOMI, M., ITO, T.,' SHIRAISHI, M. & WATANABE, Y. (1992). Inheritability of atherosclerosis and the role of lipoproteins as risk factors in the development of atherosclerosis in WHHL rabbit: risk factors related to coronary atherosclerosis are different from those related to aortic atherosclerosis. Atherosclerosis, 96, 43-52.
19. SHIOMI, M., ITO, T., TSUKADA, T., SHIRAISHI, M. & YATA, T. (1998). Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques. Arzneim Forsh/Drug Res., 48, 680-685.
20. SHIOMI, M., ITO, T., TSUKADA, T., YATA, T. & UEDA, M. (1994). Cell composition of coronary and aortic atherosclerotic lesions in WHHL rabbits differs: an immunohistochemical study. Arterioscler. Thromb., 14,931-937.
21. SHIOMI, M., ITO, T., TSUKADA, T., YATA, T., WATABABE, Y., TSUJITA, Y., FUKAMI, M., FUKUSHIGE, J., HOSOKAWA, T. & TAMURA, A. (1995). Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arlerioscler. Thromb. Vas. Biol., 15, 1938-1944.
22. SHIOMI, M., ITO, T., WATANABE, Y., TSUJITA, Y., KURODA, M., ARAI, M., FUKAMI, M., FUKUSHIGE, J. & TAMURA, A. (1990). Suppression of established atherosclerosis and xanthoma in mature WHHL rabbits by keeping their serum cholesterol levels extremely low: effect of pravastatin sodium in combination of cholestyramine. Atherosclerosis, 83, 69-80.
23. SOMA, M.R., DONETTI, E., PAROLINI, C, MAZZINI, G., FERRARI, C, FUMAGALLI, R. & PAOLETTI, R. (1993). HMG-CoA reductase inhibitors. In vivo effects on carotid intimai thickening in normocholesterolemic rabbits. Arlerioscler. Thromb., 13,571-578.
24. STEIKE, W., YAMASHITA, S., TABEI, M., AHR, H.J., BECKERMANN, B., DOMDEY-BETTE, A., GOLLER, G., SCHWARZ, T. & SIEFERT, U.M. (1996). Cerivastatin, a new inhibitor of HMG-CoA reductase; Pharmacokinetics in rats and dogs. Jpn. Pharmacol. Ther., 24, S1217-S1237.
25. VAN DER WAL, A.C., DECKER, A.E., VAN DER LOOS, CM., TIGGES, A.J. & DAS, P.K. (1994). Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept. Coronary Artery Dis., 5, 463-469.
26. VAUGHAN, C.J., MURPHY, M.B. & BUCKLEY, B.M. (1996). Statins do more than just lower cholesterol. Lancet, 348, 1079-1082.
27. WADA, H., NISHIKAWA, M., MIYANISHI, N., TSUJI, K., IKEDA, K., TAMAKI, S., IZUMI, K., YAMAGUCHI, T., SUKU, H. & DEGUCHI, K. (1996). Effects of BAY w 6228 on coagulation and fibrinolytic systems in patients with hyperlipidemia. Jpn. Pharmacol. Ther., 24, S1453-S1462 (Japanese).
28. WATANABE, Y. (1980). Serial inbreeding of rabbits with heritable hyperlipidemia (WHHL-rabbit). Atherosclerosis, 36, 261-268.
29. WATANABE, Y., ITO, T., SHIOMI, M., TSUJITA, Y., KURODA, M., ARAI.M., FUKAMI, M.&TAMURA, A. (1988). Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim. Biophys. Ada., 960,294302.
30. WEISSBERG, P.L., CLESHAM, G.J. & BENNETT, M.R. (1996). Is vascular smooth muscle cell proliferation beneficial? Lancet, 347, 305-307.